We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$250M
1-Year Est. Return
77.6%
This Fund
S&P 500
This Quarter
Est. Return
+11.07%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$185M
AUM Growth
+$54.5M
(+42%)
Cap. Flow
+$54.7M
Cap. Flow
% of AUM
29.54%
Top 10 Holdings %
Top 10 Hldgs %
73.08%
Holding
35
New
14
Increased
10
Reduced
4
Closed
6
Top Buys
| 1 |
CHMA
Chiasma, Inc. Common Stock
CHMA
|
+$16.2M |
| 2 |
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
|
+$15.5M |
| 3 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$13.6M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$11.1M |
| 5 |
Gyre Therapeutics
GYRE
|
+$9.85M |
Top Sells
| 1 |
Ligand Pharmaceuticals
LGND
|
+$32.4M |
| 2 |
AYTU BioPharma
AYTU
|
+$8.22M |
| 3 |
SCYNEXIS
SCYX
|
+$5.24M |
| 4 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$4.34M |
| 5 |
NEOS
Neos Therapeutics, Inc
NEOS
|
+$3.1M |
Sector Composition
| 1 | Healthcare | 88.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $35.2M | 18.99% |
2,523,728
+1,107,245
| +78% | +$15.5M |
|
|
ADMS
2
DELISTED
Adamas Pharmaceuticals
ADMS
| $16.4M | 8.86% |
3,418,279
+2,609,848
| +323% | +$13.6M |
|
|
CHMA
3
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $15.5M | 8.35% |
4,940,273
+4,218,966
| +585% | +$16.2M |
|
|
4
Gyre Therapeutics
GYRE
$675M
| $12.3M | 6.67% |
326,692
+215,432
| +194% | +$9.85M |
|
|
KALV
5
DELISTED
KalVista Pharmaceuticals
KALV
| $10.8M | 5.86% |
+422,310
| New | +$11.1M |
|
6
Ovid Therapeutics
OVID
$455M
| $9.98M | 5.39% |
+2,483,059
| New | +$8.25M |
|
|
CTIC
7
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $9.58M | 5.18% |
3,293,419
+1,239,419
| +60% | +$4.05M |
|
8
DiaMedica Therapeutics
DMAC
$393M
| $9.36M | 5.06% |
1,023,409
+73,409
| +8% | +$686K |
|
|
AFMD
9
DELISTED
Affimed
AFMD
| $8.15M | 4.4% |
103,000
+81,066
| +370% | +$5.26M |
|
|
APEN
10
DELISTED
Apollo Endosurgery, Inc.
APEN
| $7.98M | 4.31% |
1,448,868
-877,297
| -38% | -$4.34M |
|
|
XOMA
11
DELISTED
Xoma
XOMA
| $6.66M | 3.6% |
163,266
+39,136
| +32% | +$1.51M |
|
|
KA
12
DELISTED
Kineta, Inc. Common Stock
KA
| $6.08M | 3.28% |
47,964
+32,414
| +208% | +$4.39M |
|
|
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.41M | 2.92% |
875,180
+75,180
| +9% | +$456K |
|
|
PLXP
14
DELISTED
PLx Pharma Inc. Common Stock
PLXP
| $4.57M | 2.47% |
+506,274
| New | +$3.7M |
|
|
CFMS
15
DELISTED
Conformis, Inc. Common Stock
CFMS
| $4.39M | 2.37% |
+177,272
| New | +$4.78M |
|
16
EyePoint Inc
EYPT
$1.12B
| $3.34M | 1.81% |
+329,130
| New | +$3.7M |
|
17
Exagen
XGN
$106M
| $3.34M | 1.81% |
+191,006
| New | +$3.4M |
|
|
18
AYTU BioPharma
AYTU
$23.1M
| $2.76M | 1.49% |
18,146
-51,793
| -74% | -$8.22M |
|
19
Elicio Therapeutics
ELTX
$81.7M
| $2.44M | 1.32% |
+13,498
| New | +$2.61M |
|
|
GMDA
20
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $1.98M | 1.07% |
244,515
-134,955
| -36% | -$1.24M |
|
21
Celcuity
CELC
$4.31B
| $1.56M | 0.84% |
+109,081
| New | +$1.55M |
|
|
CFRX
22
DELISTED
ContraFect Corporation
CFRX
| $1.29M | 0.7% |
+3,364
| New | +$1.45M |
|
|
SBBP
23
DELISTED
Strongbridge Biopharma plc.
SBBP
| $1.23M | 0.66% |
445,701
-904,299
| -67% | -$2.73M |
|
24
Aptevo Therapeutics
APVO
$5.91M
| – | – |
0
| – | – |
|
25
Corvus Pharmaceuticals
CRVS
$1.25B
| $974K | 0.53% |
+316,279
| New | +$1.14M |
|
Similar funds
BIA
TGP
ER
FDDB
VM
PF
SCM
CWM
Stonepine Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Stonepine Capital Management held 35 positions worth $185M, up 42% from $131M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Stonepine Capital Management deployed $54.7M of net new capital in Q1 2021, opening 14 new positions and adding to 10 existing holdings. Its largest new stake was KalVista Pharmaceuticals: 422,310 shares worth $10.8M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 97% a quarter earlier.
On the sell side, the largest reduction was AYTU BioPharma, an estimated $8.22M trimmed.
- Stonepine Capital Management's largest Q1 2021 buy was KalVista Pharmaceuticals: 422,310 shares worth $10.8M.
- Stonepine Capital Management added most to Chiasma, Inc. Common Stock in Q1 2021, an estimated $16.2M increase.
- Stonepine Capital Management's biggest Q1 2021 reduction was AYTU BioPharma, cutting an estimated $8.22M.
- Stonepine Capital Management fully exited Ligand Pharmaceuticals in Q1 2021, selling an estimated $32.4M.
- Stonepine Capital Management's ten largest holdings make up 73% of its $185M portfolio in Q1 2021.
- Stonepine Capital Management opened 14 new positions and closed 6 in Q1 2021.
- Stonepine Capital Management's portfolio value rose 42% quarter-over-quarter to $185M.
Based on Stonepine Capital Management's 13F filing for Q1 2021, filed 14 May 2021.